ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
38.25
0.05%
US Tech 100
19,580.00
0.01%
S&P 500
5,754.47
0.16%
US Dollar vs CAD
1.34844
0.05%
Bitcoin
66,096.48
1.40%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. AstraZeneca PLC (AZN)

  7. AstraZeneca PLC (AZN) News

AZN

AstraZeneca (AZN)

AstraZeneca PLC
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:AZN
DateTimeSourceHeadlineSymbolCompany
09/26/20247:51AMGlobeNewswire Inc.Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online ViewingNASDAQ:AZNAstraZeneca PLC
09/26/20246:00AMBusiness WireTAGRISSO® (osimertinib) approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancerNASDAQ:AZNAstraZeneca PLC
09/23/20246:00AMBusiness WireDatopotamab deruxtecan final overall survival results reported in patients with metastatic HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trialNASDAQ:AZNAstraZeneca PLC
09/23/20245:44AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
09/23/20245:32AMIH Market NewsApollo Eyes $5 Billion Investment in Intel; TSMC and Samsung Explore UAE Chip Projects, and MoreNASDAQ:AZNAstraZeneca PLC
09/23/20245:27AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
09/20/20243:34PMBusiness WireFLUMIST approved for self-administration in the USNASDAQ:AZNAstraZeneca PLC
09/18/20246:00AMBusiness WireFASENRA approved in the US for eosinophilic granulomatosis with polyangiitisNASDAQ:AZNAstraZeneca PLC
09/17/202410:22AMGlobeNewswire Inc.International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024NASDAQ:AZNAstraZeneca PLC
09/16/20246:00AMBusiness WireIMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) demonstrated unprecedented overall survival in advanced liver cancer with one in five patients surviving five years in HIMALAYA Phase III trialNASDAQ:AZNAstraZeneca PLC
09/15/20249:30AMBusiness WireIMFINZI® (durvalumab) perioperative regimen reduced the risk of recurrence by 32% and the risk of death by 25% vs. neoadjuvant chemotherapy alone in muscle-invasive bladder cancer in the NIAGARA Phase III trialNASDAQ:AZNAstraZeneca PLC
09/13/20249:00AMBusiness WireENHERTU® (fam-trastuzumab deruxtecan-nxki) showed substantial clinical activity in patients with HER2-positive metastatic breast cancer and brain metastasesNASDAQ:AZNAstraZeneca PLC
09/10/20249:28AMPR Newswire (US)SOPHiA GENETICS and AstraZeneca Collaborate to Further Expand Global Access to Liquid Biopsy TestingNASDAQ:AZNAstraZeneca PLC
09/10/20249:16AMPR Newswire (US)SOPHiA GENETICS and AstraZeneca Collaborate to Further Expand Global Access to Liquid Biopsy TestingNASDAQ:AZNAstraZeneca PLC
09/10/20245:02AMIH Market NewsApple Loses EU Dispute; Google’s $2.7 Billion Fine Upheld; Oracle Shares Surge 9%NASDAQ:AZNAstraZeneca PLC
09/09/202412:50PMBusiness WireDatopotamab deruxtecan showed median overall survival of 14.6 months in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trialNASDAQ:AZNAstraZeneca PLC
09/08/202411:25AMBusiness WireNovel computational pathology-based TROP2 biomarker for datopotamab deruxtecan was predictive of clinical outcomes in patients with non-small cell lung cancer in TROPION-Lung01 Phase III trialNASDAQ:AZNAstraZeneca PLC
09/05/20245:11AMIH Market NewsQualcomm Develops Mixed Reality Glasses; Verizon to Boost Dividend, Eyes Acquisition; Samsonite Plans US Dual ListingNASDAQ:AZNAstraZeneca PLC
09/03/20246:00AMBusiness WireAstraZeneca advances ambition to improve standards of care in multiple cancer types at WCLC and ESMO 2024NASDAQ:AZNAstraZeneca PLC
08/23/20247:20AMIH Market NewsCruise and Uber Join Forces for Robotaxis, Alibaba Shifts Primary Listing to Hong Kong, Altria Hikes Dividend 4.1%NASDAQ:AZNAstraZeneca PLC
08/16/20246:00AMBusiness WireIMFINZI® (durvalumab) approved in the US for the treatment of resectable non-small cell lung cancer before and after surgeryNASDAQ:AZNAstraZeneca PLC
08/16/20245:21AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
08/15/20246:00AMBusiness WireIMFINZI® (durvalumab) granted Priority Review and Breakthrough Therapy Designation for patients with limited-stage small cell lung cancer in the USNASDAQ:AZNAstraZeneca PLC
07/30/20245:26AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
07/30/20245:00AMIH Market NewsToyota Reports Another Global Production Decline, Delta Sues CrowdStrike, Meta Launches AI Studio for Custom ChatbotsNASDAQ:AZNAstraZeneca PLC
07/29/20246:00AMBusiness WireFixed-duration CALQUENCE® (acalabrutinib) plus venetoclax, with or without obinutuzumab, significantly improved progression-free survival in 1st-line chronic lymphocytic leukemia in AMPLIFY Phase III trialNASDAQ:AZNAstraZeneca PLC
07/29/20245:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
07/25/20246:00AMBusiness WireAstraZeneca’s H1 and Q2 2024 Financial ResultsNASDAQ:AZNAstraZeneca PLC
07/25/20245:21AMIH Market NewsU.S. Index Futures Mixed After Tech Sell-Off, Oil Prices Drop on Weak China Demand and Ceasefire ExpectationsNASDAQ:AZNAstraZeneca PLC
07/25/20245:19AMIH Market NewsEarnings Updates: Ford Shares Fall 13% on EPS Miss, Stellantis Down 6%, Viking Therapeutics Up 20%, Unilever Up 5%NASDAQ:AZNAstraZeneca PLC
 Showing the most relevant articles for your search:NASDAQ:AZN

Your Recent History

TSXV
HILL
Hill
TSXV
CVB
Compass Gold
BIT
F08329
Vontobel Financial Produ...
COIN
XCHEBTC
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved